Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis
Guru Murthy G, Ball S, Feld J, Abboud R, Haddadin M, Patel S, Kishtagari A, Hawkins H, Guerra V, Dworkin E, Tawfiq R, Dulak D, Feng A, Cotte C, Cohen-Nowak A, Shukla A, Balasubramanian S, Winer E, Foucar C, Abaza Y, Shallis R, Lin C, Badar T, Patel A, Im A, Szabo A, Atallah E. Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis. Blood 2024, 144: 3206-3206. DOI: 10.1182/blood-2024-211623.Peer-Reviewed Original ResearchHMA monotherapyTumor lysis syndromePhase 3 randomized clinical trialEvent free survivalHypomethylating agentsMulticenter retrospective analysisMyelodysplastic syndromeAdverse eventsUS academic medical centersClinical trialsUpfront settingFree survivalOverall survivalClinical outcomesRetrospective analysisClinical management of myelodysplastic syndromesIncidence of tumor lysis syndromeAcademic medical centerManagement of myelodysplastic syndromesAllogeneic stem cell transplantationSingle arm clinical trialResponse rateOutpatient settingStem cell transplantationMedical Center